Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients

Autor: Jørgen Skov Jensen, Lise Haaber Thomsen, Peter Humaidan, K. Rygaard, Thor Haahr, L. Duus
Rok vydání: 2016
Předmět:
Male
0301 basic medicine
Pregnancy Rate
Denmark
Atopobium vaginae
medicine.disease_cause
Cohort Studies
0302 clinical medicine
Pregnancy
Prevalence
Medicine
Gardnerella vaginalis
Prospective Studies
Asymptomatic Infections
Family Characteristics
education.field_of_study
030219 obstetrics & reproductive medicine
biology
Rehabilitation
Obstetrics and Gynecology
Vaginosis
Bacterial

Actinobacteria
medicine.anatomical_structure
Vagina
Female
Bacterial vaginosis
Infertility
Female

Adult
medicine.medical_specialty
Population
Fertilization in Vitro
03 medical and health sciences
Humans
education
Infertility
Male

Gynecology
business.industry
medicine.disease
biology.organism_classification
Molecular Typing
Lactobacillus
Pregnancy rate
030104 developmental biology
ROC Curve
Reproductive Medicine
Nugent score
business
Zdroj: Haahr, T, Jensen, J S, Thomsen, L, Duus, L, Rygaard, K & Humaidan, P 2016, ' Abnormal vaginal microbiota may be associated with poor reproductive outcomes : A prospective study in IVF patients ', Human Reproduction, bind 31, nr. 4, s. 795-803 . https://doi.org/10.1093/humrep/dew026
ISSN: 1460-2350
0268-1161
DOI: 10.1093/humrep/dew026
Popis: Study question What is the diagnostic performance of qPCR assays compared with Nugent scoring for abnormal vaginal microbiota and for predicting the success rate of IVF treatment? Summary answer The vaginal microbiota of IVF patients can be characterized with qPCR tests which may be promising tools for diagnosing abnormal vaginal microbiota and for prediction of clinical pregnancy in IVF treatment. What is known already Bacterial vaginosis (BV) is a common genital disorder with a prevalence of approximately 19% in the infertile population. BV is often sub-clinical with a change of the vaginal microbiota from being Lactobacillus spp. dominated to a more heterogeneous environment with anaerobic bacteria, such as Gardnerella vaginalis and Atopobium vaginae. Few studies have been conducted in infertile women, and some have suggested a negative impact on fecundity in the presence of BV. Study design, size, duration A cohort of 130 infertile patients, 90% Caucasians, attending two Danish fertility clinics for in vitro fertilization (IVF) treatment from April 2014-December 2014 were prospectively enrolled in the trial. Participants/materials, setting and methods Vaginal swabs from IVF patients were obtained from the posterior fornix. Gram stained slides were assessed according to Nugent's criteria. PCR primers were specific for four common Lactobacillus spp., G. vaginalis and A. vaginae. Threshold levels were established using ROC curve analysis. Main results and the role of chance The prevalence of BV defined by Nugent score was 21% (27/130), whereas the prevalence of an abnormal vaginal microbiota was 28% (36/130) defined by qPCR with high concentrations of Gardnerella vaginalis and/or Atopobium vaginae. The qPCR diagnostic approach had a sensitivity and specificity of respectively 93% and 93% for Nugent-defined BV. Furthermore, qPCR enabled the stratification of Nugent intermediate flora. Eighty-four patients completed IVF treatment. The overall clinical pregnancy rate was 35% (29/84). Interestingly, only 9% (2/22) with qPCR defined abnormal vaginal microbiota obtained a clinical pregnancy (P = 0.004). Limitations, reasons for caution Although a total of 130 IVF patients were included in the study, a larger sample size is needed to draw firm conclusions regarding the possible adverse effect of an abnormal vaginal microbiota in relation to the clinical pregnancy rate and other reproductive outcomes. Wider implications of the findings Abnormal vaginal microbiota may negatively affect the clinical pregnancy rate in IVF patients. If a negative correlation between abnormal vaginal microbiota and the clinical pregnancy rate is corroborated, patients could be screened and subsequently treated for abnormal vaginal microbiota prior to fertility treatment. Study funding/competing interests This study was funded by The AP Moller Maersk Foundation for the advancement of Medical Science and Hospital of Central Jutland Research Fund, Denmark. No competing interests. Trial registration number The project was registered at clinicaltrials.gov (file number NCT02042352).
Databáze: OpenAIRE